Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese

Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese.

The investigators wish to determine if application of 2% lidocaine soaked gauze to the peritonsillar pillars will decrease the amount of gagging caused by awake videolaryngocope assisted tracheal intubation in the morbidly obese.

Study Overview

• Status: Unknown
• Conditions: Gagging
• Intervention / Treatment: Other: placebo; Other: lidocaine

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Albert Moore, MD; Phone Number: 34880 5149341934; Email: moore_albert@hotmail.com

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H3A1A1
      • Recruiting
      • Royal Victoria Hospital
      • Contact: Albert Moore, MD; Phone Number: 34880 5149341934; Email: moore_albert@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• morbid obese patients scheduled for bariatric surgery, with a planned awake intubation.

Exclusion Criteria:

• inability to communicate in English or french
• allergies to any study drugs
• any patient with an American society of anesthesiologists score of 4 or more

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lidocaine; Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.	Other: lidocaine; Application of lidocaine to the glossopharyngeal nerve.
Placebo Comparator: Saline; Application of saline to the glossopharyngeal nerve.	Other: placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gagging	We will assess the amount of gagging during the awake intubation.	2 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
vital signs	we will asses vital signs during intubation.	2 minutes
lidocaine levels		40 minutes

Collaborators and Investigators

• Sponsor: Royal Victoria Hospital, Canada

Study record dates

Study Major Dates

• Study Start: January 1, 2013
• Primary Completion (Anticipated): April 1, 2013
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: February 10, 2013
• First Submitted That Met QC Criteria: February 13, 2013
• First Posted (Estimate): February 15, 2013

Study Record Updates

• Last Update Posted (Estimate): February 15, 2013
• Last Update Submitted That Met QC Criteria: February 13, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Signs and Symptoms, Digestive; Gagging; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: 11-201-SDR (research ethics office)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No